FDA approves mitomycin for low-grade upper tract urothelial cancer

Pinterest LinkedIn Tumblr +

The Food and Drug Administration (FDA) approved mitomycin for adult patients with low-grade upper tract urothelial cancer (LG-UTUC).

Efficacy determination was based on OLYMPUS (NCT02793128), an ongoing, single-arm, multicenter trial enrolling 71 patients with treatment-naïve or recurrent low-grade non-invasive UTUC with at least one measurable papillary tumour located above the ureteropelvic junction.

Patients who had larger tumours could have had prior tumour debulking.

Patients received weekly mitomycin 4 mg per mL instillations via ureteral catheter or nephrostomy tube for 6 weeks.

For patients with a complete response (CR) at 3 months, instillations were to be administered monthly for a maximum of 11 additional instillations.

The major efficacy outcome measures were CR and CR durability.

CR was defined as complete absence of tumour lesions 3 months after mitomycin initiation and was assessed by urine cytology and ureteroscopy.

If warranted, a biopsy was performed.

Forty-one patients (58%) achieved a CR three months following treatment initiation and were continued in follow-up; 29 patients received at least one dose of maintenance therapy.

Durability of response in those with CRs was evaluated at 3, 6, 9 and 12 months, following the CR determination.

Seven patients had documented recurrences and nineteen patients remained in CR at 12-months following CR determination.

The median response duration had not been reached (range: 0, 18.8 months).

The most common adverse reactions (≥ 20%) in patients who received mitomycin were ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, fatigue, nausea, abdominal pain, dysuria, and vomiting.

Ureteric obstruction occurred in 58% of those receiving mitomycin and required ureteral stent placement in 88% of these patients.

The recommended mitomycin dose is 4 mg per mL instilled via ureteral catheter or nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not exceeding 15 mL (60 mg mitomycin).

Source: The Food and Drug Administration (FDA)


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.